... 2 readers Save reference to library · Related research. The Business of Sustainability. The B... more ... 2 readers Save reference to library · Related research. The Business of Sustainability. The Business in Sloan Management Review (2004). 2 readers Save reference to library · Related research. More related papers. Cite this document (BETA). ... APA. BibTeX. Cell. Chicago. Harvard ...
Corporate Social Responsibility and Environmental Management, 2009
... Sandra Waddock, Bradley Googins, Charles Levenstein, and Rich Liroff, for reviewing the draft... more ... Sandra Waddock, Bradley Googins, Charles Levenstein, and Rich Liroff, for reviewing the draft tool and providing expert feedback on the topics and questions; and the Assessment Tool workgroup including Josh Shortlidge, Susan Thomas, Colleen Olphert, Alyssa Dver, Chris ...
... 2 readers Save reference to library · Related research. The Business of Sustainability. The B... more ... 2 readers Save reference to library · Related research. The Business of Sustainability. The Business in Sloan Management Review (2004). 2 readers Save reference to library · Related research. More related papers. Cite this document (BETA). ... APA. BibTeX. Cell. Chicago. Harvard ...
Corporate Social Responsibility and Environmental Management, 2009
... Sandra Waddock, Bradley Googins, Charles Levenstein, and Rich Liroff, for reviewing the draft... more ... Sandra Waddock, Bradley Googins, Charles Levenstein, and Rich Liroff, for reviewing the draft tool and providing expert feedback on the topics and questions; and the Assessment Tool workgroup including Josh Shortlidge, Susan Thomas, Colleen Olphert, Alyssa Dver, Chris ...
This case focuses on the problem of antibiotic resistance and examines the challenges faced by ph... more This case focuses on the problem of antibiotic resistance and examines the challenges faced by pharmaceutical companies involved in new antibiotics discovery and development. It features a publicly held research and development (R&D) pharmaceutical company based in the United States that has been a leader in developing antibiotics for decades, but in recent years began shifting its focus to more profitable drugs. As it considers its business strategy for the next 5–10 years, the company must weigh the costs and benefits of continuing to invest in new antibiotics. What are the main challenges that it must overcome to ensure return on its antibiotics’ investments? What are some emerging opportunities and key stakeholders to partner with? What policy and other actions are needed to prevent the ...
Uploads
Papers by Vesela Veleva